Could a simple blood test track nerve damage? a study investigates NT-3 levels in neuropathy.
NCT ID NCT05011006
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study measures levels of a protein called NT-3 in the blood of people with peripheral neuropathy or Charcot-Marie-Tooth disease. Researchers will compare these levels with measures of muscle strength, mobility, and daily function. The goal is to see whether NT-3 levels correlate with how well the nerves and muscles are working.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If a link is found, NT-3 levels might become a useful marker for tracking neuropathy severity or guiding future treatments.
- What could go wrong
- This is a very small observational study with only 8 participants, so any patterns seen may not apply to larger groups. It does not test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
8 people
The number who actually took part.
- Started
-
Jan 2020
- Finished
-
Nov 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Male and female subjects, from 7 years of age and over with a definitive diagnosis of acquired peripheral neuropathy or genetically determined CMT neuropathy
- Ages
-
7 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males or females from 7 years of age or older * Diagnosis of acquired peripheral neuropathy (PN) such as due to diabetes, chemo-induced, autoimmune chronic inflammatory demyelinating polyneuropathy (CIDP) established by a report of electrical studies or with a known genetic CMT diagnosis. Definitive diagnosis of PN is established with a report of electrical studies, EMG/nerve conduction studies.2 * Perform assessments to the best of their ability with reliable results as deemed by the evaluator. * Ability to attend scheduled appointments * Ability to provide informed consent (or assent for ages 9-18) Exclusion Criteria: * Current pregnancy per medical history * Has a medical condition or extenuating circumstances that, in the opinion of the investigator, might compromise the subject's wellbeing, safety, or clinical interpretability
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Charcot-Marie-Tooth disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Global registry aims to map the full course of Charcot-Marie-Tooth disease
- Ultrasound probes nerve stiffness in rare nerve diseases
- Robots map how brain and nerve injuries disrupt everyday arm tasks
- Cold therapy may offer relief for Chemotherapy-Induced nerve pain in children
- Can a new antibody calm the immune attack in CIDP?
- Wearable insoles warn of foot pressure to stop diabetic ulcers